Announcement • May 01
Ocumetics Technology Corp. announced that it expects to receive CAD 1.54 million in funding Ocumetics Technology Corp announced a private placement of up to 2,800,000 units of the Corporation at a price of CAD 0.55 per Unit for gross proceeds of up to CAD 1,540,000 on April 29, 2026. Each Unit will consist of one common share in the share capital of the Corporation (“Common Share”) and one common share purchase warrant (“Warrant”). Each Warrant will entitle the holder to purchase one additional Common Share at an exercise price of CAD 0.75 for a period of three years from the date of issuance of the Warrant. The Corporation may pay finders fees to those who assist the Corporation in filling the Private Placement. The Offering is expected to close in tranches. Common Shares and Warrants issued under the Offering will be subject to a hold period expiring four months and one day following their respective date of issue. Announcement • Dec 24
Ocumetics Technology Corp., Annual General Meeting, Feb 06, 2026 Ocumetics Technology Corp., Annual General Meeting, Feb 06, 2026. Recent Insider Transactions Derivative • Oct 07
CFO & Director exercised options to buy CA$2.1m worth of stock. On the 3rd of October, Roger Jewett exercised options to buy 2m shares at a strike price of around CA$0.12, costing a total of CA$219k. This transaction amounted to 648% of their direct individual holding at the time of the trade. Roger currently holds 1.89m shares (0.01506070670725128 of the company). Company insiders have collectively bought CA$422k more than they sold, via options and on-market transactions, in the last 12 months. New Risk • Aug 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 26% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.2m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Negative equity (-CA$4.0m). Earnings have declined by 24% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$65.9m market cap, or US$47.5m). New Risk • Jul 29
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.2m free cash flow). Negative equity (-CA$4.0m). Earnings have declined by 24% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$48.6m market cap, or US$35.3m). Announcement • Jul 10
Ocumecs Technology Corp. Completes Staff Training for First-In-Human Clinical Study of Accommodaing Intraocular Lens Ocume cs Technology Corp. announced that it has completed training of the clinical team at its first study site in Mexico City. This training is in preparation for the upcoming first-in-human (FIH) clinical study of the Ocumetics accommodating intraocular lens. This training marks a critical milestone in Ocumetics' 18-year journey toward regulatory approval of a transformative accommodating intraocular lens technology intended to restore vision for patients undergoing cataract extraction. The training program is designed to ensure that all participating staff members are equipped with the specialized skills and knowledge necessary to implant the Ocumetics Lens with precision and safety. The Ocumetics Lens is designed to restore the ability to see both distant and near objects clearly without glasses following cataract surgery. The training program covers every phase of the clinical trial process, including pre-operative assessment, lens handling, surgical technique, and post-operative care. Using proven training methods, the curriculum ensures successful execution of the first clinical study of this novel technology. With clinical team training completed, and ethics committee approval pending, Ocumetics is poised to launch its historic FIH trial-an essential step toward clinical validation and eventual regulatory approval to market the Ocumetics Lens. Announcement • Jun 05
Ocumecs Technology Corp. Targets June 26, 2025 for Commencement of its First in Human Study Ocumetics Technology Corp. announced that it has set June 26, 2025 as the date for its first-in-human (FIH) clinical study. The FIH clinical study involves the implantation of the Company's inaugural accommodating intraocular lens (the "Ocumetics Lens") in the first group of study patients at a designated clinic in Mexico City. This milestone marks a historic moment for Ocumetics - culminating nearly two decades of relentless innovation, research, and development. For the first time in its 18-year history, Ocume cs will see its breakthrough accommodating intraocular lens implanted in human subjects, setting the stage for a new era in vision restoration. The Ocumetics Lens is designed to restore the eye's natural ability to shift focus from distance to near and back again, offering a potential paradigm shift in vision correction. The study will be conducted in collaboration with the Company's regulatory research consultants, whose expertise has been instrumental in ensuring readiness at the proposed site in Mexico City. The targeted FIH implantation date was set after consideration of lens manufacturing and testing procedures, study site preparation, staff training, regulatory application submission, and approval timelines. With this critical milestone in sight, Ocumetics moves one step closer to demonstrating the safety and performance of the Ocumetics Lens in a real-world clinical setting - laying the groundwork for future regulatory submissions and readiness for commercial distribution. Announcement • Jun 04
Ocumetics Technology Corp. announced that it expects to receive CAD 2.1 million in funding Ocumetics Technology Corp. announced a best efforts private placement that it will issue up to 6,000,000 units of the Corporation at an issue price of CAD 0.35 per unit for the gross proceeds of up to CAD 2,100,000 on June 4, 2025. Each Unit will consist of one common share in the share capital of the Corporation and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional Common Share at an exercise price of CAD 0.50 for a period of 24 months from the date of issuance of the Warrant. The Warrants will be subject to an acceleration clause such that if the volume weighted average trading price of the Common Shares on the TSX Venture Exchange is at least CAD 0.60 per Common Share for a period of 30 consecutive trading days. The company will pay a cash commissions equal to 7% of the gross proceeds of the Offering received from investors introduced by Numus Capital to the Corporation and 4% of the gross proceeds of the Offering received from investors sourced by the Corporation. The Offering is expected to close in tranches. Common Shares, Warrants and Agent’s Warrants issued under the Offering will be subject to a hold period expiring four months and one day following their respective date of issue. Announcement • Jun 03
Ocumetics Technology Corp. Announces Mexico City as Site for Its First in Human Study Ocumetics Technology Corp. announced that the first-in-human (FIH) clinical study for its revolutionary accommodating intraocular lens will take place in Mexico City. This follows a strategic decision to relocate the study from its originally planned site in the Dominican Republic that will allow Ocumetics to take advantage of resources that better meet the Company's needs. Preparations are currently underway to activate the clinical site in Mexico City, including staff training, regulatory submissions, and logistical planning. Ocumetics remains on track to begin human implantation of its novel accommodative intraocular lens in the summer of 2025. Announcement • May 12
Ocumecs Technology Corp. Announces Lens Design Freeze for First-In-Human Study Ocume cs Technology Corp. announced the successful completion of its optimized lens prototype design. With this milestone, Ocumetics has formally initiated a design freeze - locking in lens specifications that will be used in its upcoming first-in-human (FIH) clinical study planned for summer 2025. This decision follows a series of rigorous design optimizations, bench testing, and laboratory performance validations, including recent success in achieving the accommodative response necessary to proceed with first-in-human trials. The finalized prototype integrates Ocumetics' most advanced optical design, biomechanical engineering, and proprietary manufacturing methods, representing a new era in accommodative intraocular lens technology. The finalized design will now undergo final manufacturing scale-up and sterility validation procedures to prepare for clinical-grade production. The FIH study is a critical next step in Ocumetics' mission to provide a revolutionary solution for patients seeking freedom from glasses, contact lenses, and traditional intraocular implants. Announcement • Mar 12
Ocumetics Technology Corp. Appoints Michael Edwards to its Board of Directors Ocumetics Technology Corp. announced that it has appointed Michael Edwards, BBA, CPA, CA, CLU, to its Board of Directors. Michael has an extensive background in accounting, taxation, corporate governance and fundraising in Canada. Michael graduated from Acadia University with a Bachelor of Business Administration and thereafter obtained his C.A. designation, achieving the highest provincial standing (PEI) on the Uniform Final Exams. Michael spent several years working for public accounting firms in increasing areas of responsibility, and completed the CICA In-Depth Tax Course. Michael was previously the Canadian Tax Manager for Michelin Tires Canada Ltd. and the Vice President, Finance for a regional residential/commercial real estate development company before returning to public accounting practice. Thereafter, he became a licensed life agent, obtained the Chartered Life Underwriter CLU designation, and currently holds a life brokers contract for several major life companies through Customized Insurance &Tax Solutions Inc. Currently, Michael is insurance life licensed and a registered Dealing Representative of Pinnacle Wealth Brokers Ltd. Michael specializes in insurance and exempt market investment products and is President and Director of EDC Tax Services Inc. New Risk • Jan 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.4m free cash flow). Negative equity (-CA$1.7m). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (CA$39.5m market cap, or US$27.3m). New Risk • Nov 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.4m free cash flow). Negative equity (-CA$1.7m). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$40.1m market cap, or US$28.6m). Announcement • Sep 10
Ocumetics Technology Corp., Annual General Meeting, Nov 08, 2024 Ocumetics Technology Corp., Annual General Meeting, Nov 08, 2024. New Risk • Jun 04
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$235k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$235k). Earnings have declined by 41% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Market cap is less than US$100m (CA$35.3m market cap, or US$25.8m). Announcement • May 17
Ocumetics Technology Corp. announced that it expects to receive CAD 3.76 million in funding Ocumetics Technology Corp. announced a non-brokered private placement of secured convertible debentures having an aggregate face value principal amount of up to CAD 4,000,000 for gross proceeds of CAD 3,760,000 on May 15, 2024. The debentures will be subject to an original issue discount of 6%. The debentures will bear interest at rate of 18% per annum, compounded annually. The debentures will mature, and principal and interest will be payable by the corporation, on the date which is two years from the date of issue. The corporation may prepay the indebtedness under the debentures at any time upon ninety (90) days prior written notice, without penalty. The principal will be convertible at the option of the holder into common shares of the corporation at a conversion price of CAD 0.32 per share. Interest will be convertible into common shares of the issuer pursuant to shares for debt applications, from time to time, at the option of the debenture holders. The debentures and the common shares issuable upon the conversion of the debentures will be subject to a four month hold period. The completion of the offering is subject to the final approval of the TSX Venture Exchange. Announcement • Jan 17
Ocumetics Technology Corp. announced that it has received CAD 0.4166 million in funding On January 17, 2024, Ocumetics Technology Corp. closed the transaction. The company issued 1,301,875 units at an issue price of CAD 0.32 per unit for gross proceeds of CAD 416,600. Each unit will consist of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share at an exercise price of CAD 0.64 for a period of two years from the date of issuance of the warrant. The company paid finders fees to Leede Jones Gable Inc. consisting of cash commissions of CAD 200. All securities issued under the Private Placement are subject to a hold period of four months and one day. Announcement • Dec 09
Ocumetics Technology Corp. Announces Successful Completion of Animal Study in Preparation for Its First-In-Human Study, Anticipated to Commence in First Quarter of 2024 in the Dominican Republic Ocumetics Technology Corp. confirmed the successful completion of its biocompatibility animal study, in preparation for its first-in-human study, anticipated to commence in first quarter of 2024 in the Dominican Republic. The biocompatibility of the Ocumetics accommodating intraocular lens (the "Ocumetics Accommodating Lens") was evaluated by surgical implantation of two lenses into the eyes of rabbits. The first lens, the Ocumetics Accommodating Lens, was compared to the second lens, a commercially available monofocal intraocular lens ("IOL") as a control. Results from this three-month animal study demonstrated that there were no biocompatibility or safety issues related to the Ocumetics Accommodating Lens when compared to the control IOL. The study also evaluated the occurrence of anterior and posterior capsular opacification in the rabbit model over the three month period. There were no significant differences between the two IOL groups in terms of posterior capsular opacification and anterior capsular opacification at the end of the study. Announcement • Nov 17
Ocumetics Technology Corp. announced that it expects to receive CAD 1 million in funding Ocumetics Technology Corp. announced a non-brokered private placement of up to 3,125,000 units of at a price of CAD 0.32 per unit for gross proceeds of up to CAD 1,000,000 on November 15, 2023. Each unit will consist of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share at an exercise price of CAD 0.64 for a period of two years from the date of issuance of the warrant. The company may pay finder’s fees on all or a portion of the private placement to eligible persons seeking subscribers to the financing, all in accordance with applicable securities laws and the policies of the TSX Venture Exchange. New Risk • Oct 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (7.1% increase in shares outstanding). Market cap is less than US$100m (CA$40.9m market cap, or US$30.0m). Announcement • Sep 20
Ocumetics Continues to Meet Significant Development Milestones Lens Design Optimized for Upcoming First in Human Study Ocumetics Technology Corp. confirms a remarkable achievement in the optimization of its vision correction technology - the Ocumetics Accommodating Lens. Through rigorous research and development efforts over the past two years, Ocumetics has modified its lens design five times, ultimately arriving at its final lens configuration version 10.5. Lens version 10.5 has been tested in vitro and in an animal model, and will be used in Ocumetics' upcoming human clinical trials. This achievement is a testament to Ocumetics' persistence and unwavering commitment to delivering the most advanced and efficient vision correction solution possible. The optimization process has been conducted with a meticulous focus on quality and performance, ensuring that the upcoming first-in-human study, anticipated to commence in First Quarter 2024 in the Dominican Republic, will benefit from the most advanced technology available. Announcement • Jul 01
Ocumetics Technology Corp., Annual General Meeting, Aug 25, 2023 Ocumetics Technology Corp., Annual General Meeting, Aug 25, 2023. Announcement • Jun 23
Ocumetics Technology Corp. announced that it expects to receive CAD 1 million in funding Ocumetics Technology Corp. announced a non-brokered private placement and will issue up to 3,333,333 units at an issue price of CAD 0.3 per common share for gross proceeds of up to CAD 999,999.9 on June 22, 2023. Each unit will consist of one common share in the share capital of the corporation and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share at an exercise price of CAD 0.6 for a period of two years from the date of issuance of the warrant. There will be no minimum subscription level for this offering. In the event that aggregate subscriptions for units under the offering exceed the maximum number of securities to be distributed, then units will be sold to qualifying subscribers on a pro rata basis based on the number of units subscribed for. Insiders may participate in the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after closing of the offering. The offering may include finder’s fees commission’s payable in cash and/or securities and is subject to approval of the TSX Venture Exchange. Announcement • Feb 15
Ocumetics Technology Corp. Announces Successful Completion of Animal Studies Ocumetics Technology Corp. announced the successful completion of its latest animal studies. The lens design met and exceeded its expectations. This is the first in a series of biocompatibility studies, the second of which is scheduled to commence in March 2023. The biocompatibility studies will take 3 months to complete, which means it should be able to begin first-in-human proof of concept studies in July or August of 2023. Announcement • Feb 02
Ocumetics Technology Corp. announced that it has received CAD 0.672108 million in funding Ocumetics Technology Corp. announced the closing of a non-brokered private placement of 1,493,574 units at a price of CAD 0.45 per unit for gross proceeds of CAD 672,108.15 on February 1, 2023. Each unit will consist of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share at an exercise price of CAD 0.90 for a period of two years from the date of issuance of the warrant. The company may paid finder’s fees of CAD 4,185 in accordance with applicable securities laws and the policies of the TSX Venture Exchange. All securities issued in connection with the transaction will be subject to a statutory hold period expiring four months and one day. Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Bob Quinn is the most experienced director on the board, commencing their role in 2021. Independent Director Sandi Gilbert was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Announcement • Oct 21
Ocumetics Technology Corp. announced that it expects to receive CAD 2.25 million in funding Ocumetics Technology Corp. announced a non-brokered private placement of 5,000,000 units at a price of CAD 0.45 per unit for gross proceeds of CAD 2,250,000 on October 19, 2022. Each unit will consist of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share at an exercise price of CAD 0.90 for a period of two years from the date of issuance of the warrant. The company may pay finder’s fees on all or a portion of the private placement to eligible persons seeking subscribers to the financing, all in accordance with applicable securities laws and the policies of the TSX Venture Exchange. Announcement • Aug 30
Ocumetics Technology Corp.' Lens Technology Delivers 14-Diopters of Accommodation in Bench Studies Ocumetics Technology Corp. provided an update to its lens optimization efforts. In addition, Ocumetics has worked to optimize the delivery system for injecting Ocumetics' lens technology into the eye. Preclinical trials for Ocumetics lens technologies are anticipated to be completed in Fourth Quarter 2022, which would allow the first human studies to begin in First Quarter 2023. Full clinical trials are expected to start immediately thereafter in the summer of 2023. Announcement • May 26
Ocumetics Technology Corp. Provides an Update on Preclinical Bench Test Results of its Lens Technologies Ocumetics Technology Corp. provided an update on preclinical bench test results of its lens technologies. In recent bench tests conducted by Ocumetics, the Company's latest accommodating lens design consistently achieved 12 diopters of accommodation, which allows the eye to focus on objects less than 4 inches away. Preclinical studies for Ocumetics' accommodating lens technology are scheduled to be completed in Third Quarter 2022. The first proof-of-concept human studies are expected to begin shortly thereafter, in fourth quarter of 2022. Full clinical trials are expected to begin in 2023. Announcement • May 20
Ocumetics Technology Corp. Provides Update on Preclinical Studies Ocumetics Technology Corp. provided an update on the status of preclinical studies for its first product, the Bionic Lens. Since January 2022, Ocumetics has been busy undertaking a series of studies using cadaver donor eyes to determine how Ocumetics' optical technologies would fit in the human eye. These studies have led to design enhancements to perfect how the Bionic Lens conforms to the lens capsular bag of the human eye. The studies, and resulting design enhancements, were supervised by Ocumetics' regulatory approval expert, Dr. Barbara Fant, Ocumetics' founder and Chief Scientific Officer, Dr. Garth Webb, and Chief Medical Officer, Dr. Doyle Stulting. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Sandi Gilbert was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 02
Ocumetics Technology Corp., Annual General Meeting, May 25, 2022 Ocumetics Technology Corp., Annual General Meeting, May 25, 2022. Announcement • Feb 04
Ocumetics Announces Commencement of Regulatory Strategy Project with Clinical Research Consultants, Inc Ocumetics Technology Corp. announced the commencement of its project with Clinical Research Consultants Inc. of Cincinnati, Ohio. CRC and Ocumetics have entered into a consulting agreement whereby CRC will provide general regulatory, clinical, data management, statistical, quality and technical consulting services to Ocumetics to develop, support and implement the regulatory strategy for the Bionic LensTM. Announcement • Jan 13
Ocumetics Technology Corp. Provides Update on Preclinical Studies Ocumetics Technology Corp. provided an update on the status of preclinical studies for its first product, the Bionic Lens. Successful preclinical studies will be followed by Phase 1 human clinical trials, starting with a planned Proof-of-Concept study in the Fall of 2022. Test the Bionic Lens retainer for structural integrity and ease of insertion by the surgeon. Test the Bionic lens retainer with a standard lens used in a typical cataract procedure. Test the Bionic Lens retainer and the Bionic Lens optic element together. Commenced Oct. 22/21. Analysis completed in October 2021. Scheduled to begin February 25, 2022. Scheduled to begin March 25, 2022. Study completed Oct/21. Design improvements completed Dec/21. Research report expected June/22. Research report expected June/22. Board Change • Sep 13
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 